Results 101 to 110 of about 184,347 (251)

Benchmarking imputation strategies for missing time-series data in critical care using real-world-inspired scenarios

open access: yesScientific Reports
Handling missing data remains a central challenge in Intensive Care Units (ICU) time-series analysis, where gaps frequently arise from non-random mechanisms such as sensor disconnections and workflow-driven interruptions.
Michael Poette   +5 more
doaj   +1 more source

Exposure–Response Analysis of Enfortumab Vedotin Plus Pembrolizumab as First‐Line Therapy for Locally Advanced or Metastatic Urothelial Cancer

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Enfortumab vedotin is a nectin‐4‐directed antibody–drug conjugate currently approved in combination with pembrolizumab for the first‐line treatment of locally advanced or metastatic urothelial cancer. Here we describe the exposure–response relationship between enfortumab vedotin exposures and efficacy/safety endpoints in patients who received ≥1 dose ...
Vaishali L. Chudasama   +9 more
wiley   +1 more source

A contemporary simple risk score for prediction of severe acute kidney injury after heart transplantation

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1166-1175, April 2025.
A contemporary simple risk score for prediction of severe AKI after HT. Abstract Background The aim of this study was to develop a simple risk score to estimate severe acute kidney injury (AKI) risk based on a large contemporary heart transplantation (HT) cohort.
Shuangshuang Zhu   +10 more
wiley   +1 more source

Interventional therapies for chronic heart failure: An overview of recent developments

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1081-1094, April 2025.
Abstract Heart failure (HF), the final manifestation of most cardiovascular diseases, has become a major global health concern, affecting millions of individuals. Despite basic drug treatments, patients present with high morbidity and mortality rates. However, recent advancements in interventional therapy have shown promising results in improving the ...
Bingchen Guo   +7 more
wiley   +1 more source

Clinical trial barriers in neurostimulation for pediatric drug‐resistant epilepsy

open access: yesEpileptic Disorders, EarlyView.
Abstract Objective The NeuroPace responsive neurostimulation (RNS) System effectively treats focal drug‐resistant epilepsy (DRE) in adults but lacks pediatric regulatory approval. Despite effective off‐label pediatric use, systemic device‐trial challenges have impeded label expansion.
Mira C. Hasner   +15 more
wiley   +1 more source

Patient Perspectives and Concerns Regarding Cataract Surgery and Cataract Surgery Sedation: A Qualitative Study

open access: yesClinical Ophthalmology
Liam Molina,1 Nora Lyang,2 Rachel Schwartz,1,3 Neeti Parikh,1,4 Saras Ramanathan,1,4 Alison J Huang,1,5,6 Catherine L Chen1,3,7 1School of Medicine, University of California San Francisco, San Francisco, CA, USA; 2Western University of Health Sciences ...
Molina L   +6 more
doaj  

Perils and progress in epilepsy surgery utilization: Twenty‐five years later

open access: yesEpilepsia, EarlyView.
Abstract More than 25 years have passed since the first randomized controlled trial (RCT) established that surgery is superior to continued anti‐seizure medication (ASM) for drug‐resistant temporal lobe epilepsy, and nearly as long since a joint practice parameter urged that appropriate surgical candidates be referred to a specialized center for ...
Dario J. Englot
wiley   +1 more source

Monthly or menstrual? A scoping review of catamenial epilepsy and non‐menstrual seizure rhythms

open access: yesEpilepsia, EarlyView.
Abstract Objective Despite the reported high prevalence of catamenial epilepsy (CE), the condition remains poorly defined, with lack of consensus on what entails a menstrual‐related seizure exacerbation. Emerging evidence of multiday cycles of seizure activity, including about‐monthly cycles, present in both men and women, further confound the ...
Victoria Wong   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy